Hexalogen Bio Secures New Funding to Accelerate iPSC-Derived Regenerative Platelet Therapeutics

Currently, the "artificial blood" cell products internationally are still in the early stages of industrialization from 0 to 1.The induced pluripotent stem cell technology of Renerval Therapeutics is at an internationally leading level., the successful industrialization of these products will bring revolutionary, world-leading blood cell products, completely solving the long-standing shortage of blood transfusion products in China's clinics. In special situations such as disasters and wars, platelets and red blood cells, as strategic reserve materials, their regenerative products not only have significant clinical and economic value but also are crucial to national interests.

Renerval Therapeutics has currentlyApplied for and authorized multiple independently developed patents, and is one of the main drafting units of China's first group standard, "General Requirements for Human-derived Cell Storage Services."，In September 2023, won the "Haiju Yingcai" Global Innovation and Entrepreneurship Competition Finals (Entrepreneurship Track)Silver Cluster Award", winning the China Innovation and Entrepreneurship Competition in the same yearShanghai Excellence Enterprise Award and National Excellence Award, officially became in July 2024Shanghai Pudong New Area Postdoctoral Innovation Practice Base Hosting UnitIn addition, Renerval Therapeutics has established a strategic partnership with AOPU Biotech, a STAR Market listed company, this year to jointly tackle and fully replace imported raw materials and culture media upstream of the company's main product pipeline with domestically produced alternatives.Accelerate the Industrialization Layout of Regenerative Platelets。

Chen Junfeng, Ph.D., CEO of Renerval Therapeutics, stated:"Since its establishment, Renerval Therapeutics has always adhered to the mission of 'innovative technology, serving humanity,' and is committed to transforming cutting-edge iPSC technology into clinical-grade artificial blood cell products and internationally leading anti-aging services. We sincerely thank the investors in this round for their recognition and support, whose participation has injected new momentum into our development. The Renerval team will seize this opportunity to further accelerate the clinical progress of our artificial platelet pipeline, ensuring that our innovative products can benefit a wide range of patients as soon as possible. We firmly believe that through relentless efforts and continuous innovation, Renerval Therapeutics will play an increasingly important role in the future of life sciences and contribute to the advancement of human health."